These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11883527)

  • 1. Treatment of Epstein-Barr virus-associated malignancies with specific T cells.
    Gottschalk S; Heslop HE; Roon CM
    Adv Cancer Res; 2002; 84():175-201. PubMed ID: 11883527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Epstein-Barr virus-associated cancers in children.
    Straathof KC; Bollard CM; Rooney CM; Heslop HE
    Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy for EBV-associated malignancies.
    Gottschalk S; Heslop HE; Rooney CM
    Leuk Lymphoma; 2005 Jan; 46(1):1-10. PubMed ID: 15621775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive cell therapy against EBV-related malignancies: a survey of clinical results.
    Merlo A; Turrini R; Dolcetti R; Zanovello P; Amadori A; Rosato A
    Expert Opin Biol Ther; 2008 Sep; 8(9):1265-94. PubMed ID: 18694349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE; Moss DJ
    Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic strategies for EBV-associated malignancies.
    Khanna R; Tellam J; Duraiswamy J; Cooper L
    Trends Mol Med; 2001 Jun; 7(6):270-6. PubMed ID: 11378517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus.
    Paludan C; Münz C
    Curr Mol Med; 2003 Jun; 3(4):341-7. PubMed ID: 12776989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
    Sun Q; Burton R; Reddy V; Lucas KG
    Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell recognition of Epstein-Barr virus associated lymphomas.
    Rickinson AB; Murray RJ; Brooks J; Griffin H; Moss DJ; Masucci MG
    Cancer Surv; 1992; 13():53-80. PubMed ID: 1330300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
    Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
    Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells.
    Rooney CM; Roskrow MA; Suzuki N; Ng CY; Brenner MK; Heslop H
    Ann Oncol; 1998; 9 Suppl 5():S129-32. PubMed ID: 9926252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
    Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
    Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for Epstein-Barr virus-associated cancers.
    Rooney CM; Roskrow MA; Smith CA; Brenner MK; Heslop HE
    J Natl Cancer Inst Monogr; 1998; (23):89-93. PubMed ID: 9709309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for EBV-associated malignancies.
    Merlo A; Turrini R; Dolcetti R; Zanovello P; Rosato A
    Int J Hematol; 2011 Mar; 93(3):281-293. PubMed ID: 21336546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
    Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
    Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
    J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
    Wagner HJ; Bollard CM; Vigouroux S; Huls MH; Anderson R; Prentice HG; Brenner MK; Heslop HE; Rooney CM
    Cancer Gene Ther; 2004 Feb; 11(2):81-91. PubMed ID: 14685154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell therapies.
    Gottschalk S; Bollard CM; Straathof KC; Louis CU; Savoldo B; Dotti G; Brenner MK; Heslop HE; Rooney CM
    Ernst Schering Found Symp Proc; 2006; (4):69-82. PubMed ID: 17824182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.